Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928655 | 0.76 | SMN1; SMN2 (0.45) | SMN1; SMN2NOS1GLAADORA2APDE10A | |
| SCHEMBL6890297 | 0.75 | NOS1 (0.38) | NOS1ADORA2AGABRA1GABRG2GABRB3 | |
| SCHEMBL5064948 | 0.74 | ADORA2A (0.40) | NOS1ADORA2AALDH1A1HPGDHSD17B10 | |
| SCHEMBL2745632 | 0.72 | ATAD2 (0.44) | SMN1; SMN2GLAADORA2AMIFGABRA1 | |
| SCHEMBL13680755 | 0.71 | CYP2E1 (0.44) | GLAADORA2AMIFGABRA1GABRG2 | |
| SCHEMBL22008 | 0.69 | — | — | |
| SCHEMBL1231792 | 0.69 | ATAD2 (0.37) | — | |
| SCHEMBL30609151 | 0.69 | — | — | |
| SCHEMBL5068132 | 0.68 | IDO1 (0.38) | SMN1; SMN2ADORA2ARAB9ANPC1KDM4E | |
| SCHEMBL5069269 | 0.68 | NPC1 (0.49) | NOS1ADORA2ARAB9ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653248-B2 | 2-aminopyridine and 2-pyridone C-nucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-0869937-A4 | NOVEL AMIDE-BASED CATIONIC LIPIDS | PROMEGA BIOSCIENCES INC (US) | 2004-07-21 | — | — | EP | disclosed |
| US-6670393-B2 | For delivery of macromolecules into cells | PROMEGA BIOSCIENCES, INC. | 2003-12-30 | — | — | US | disclosed |
| US-6638529-B2 | Lipid copound for use in the transfer macromolecules in cells | GENTA INCORPORATED | 2003-10-28 | — | — | US | disclosed |
| US-6610664-B2 | Amides and chemical intermediates used for lipofection of nucleic acids or peptides into prokaryotic or eukaryotic cells; drug delivery | ISIS PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030120065-A1 | 2-aminopyridine and 2-pyridone C-nucleosides | ISIS PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| EP-0968227-B1 | DIMERIC CATIONIC LIPIDS ON DICYSTINE BASIS | PROMEGA BIOSCIENCES INC (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030097011-A1 | Novel carbamate-based cationic lipids | PROMEGA BIOSCIENCES, INC. (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030069392-A1 | Cationic lipids | LIN KUEI-YING (US) | 2003-04-10 | — | — | US | disclosed |
| US-6495672-B1 | DIAGNOSIS AND SEPARATION THROUGH TRIPLEX BINDING | ISIS PHARMACEUTICALS, INC. | 2002-12-17 | — | — | US | disclosed |
| EP-0840744-A1 | PHOSPHONIC ACID-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1998-05-13 | — | — | EP | disclosed |
| EP-0830368-A1 | NOVEL CARBAMATE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1998-03-25 | — | — | EP | disclosed |
| US-5705693-A | LIPIDS WITH CATIONS FOR GENETIC ENGINEERING, FORMING PEPTIDES INTO PROKAROTIC OR EUKAROTIC CELLS | GILEAD SCIENCES, INC. (US) | 1998-01-06 | — | — | US | disclosed |
| WO-1997049723-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACID TO CELLS | GILEAD SCIENCES, INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1996040726-A9 | NOVEL CARBAMATE-BASED CATIONIC LIPIDS | — | 1997-02-06 | — | — | WO | disclosed |
| WO-1997003939-A1 | NOVEL AMIDE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1997-02-06 | — | — | WO | disclosed |
| WO-1996040725-A1 | PHOSPHONIC ACID-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040726-A1 | NOVEL CARBAMATE-BASED CATIONIC LIPIDS | GENTA INCORPORATED (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996001841-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | GILEAD SCIENCES, INC. (US) | 1996-01-25 | — | — | WO | disclosed |
| WO-1996001840-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | GILEAD SCIENCES, INC. (US) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069392-A1 | Cationic lipids | PHOSPHO1, CETP, PCTP | SMN1; SMN2 4824/4885NOS1 3721/4885GLA 2941/4885 |
| US-20030120065-A1 | 2-aminopyridine and 2-pyridone C-nucleosides | NT5C2, NT5C3B, TYMP | SMN1; SMN2 599/4885NOS1 4336/4885GLA 4402/4885 |
| US-20030097011-A1 | Novel carbamate-based cationic lipids | SGMS1, CETP, PCYT1A | SMN1; SMN2 4629/4885NOS1 3359/4885GLA 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.